Sharon Lewin
#76,778
Most Influential Person Now
Australian infectious disease physician and researcher
Sharon Lewin's AcademicInfluence.com Rankings
Sharon Lewinphilosophy Degrees
Philosophy
#7276
World Rank
#10467
Historical Rank
Logic
#4334
World Rank
#5613
Historical Rank
Download Badge
Philosophy
Sharon Lewin's Degrees
- Bachelors Medicine University of Melbourne
- PhD Immunology University of Melbourne
Why Is Sharon Lewin Influential?
(Suggest an Edit or Addition)According to Wikipedia, Sharon Ruth Lewin , is an Australian physician who is the inaugural Director of The Peter Doherty Institute for Infection and Immunity . She is also a Professor of Medicine at The University of Melbourne, a National Health and Medical Research Council Practitioner Fellow, Director of the Cumming Global Centre for Pandemic Therapeutics, and President of the International AIDS Society .
Sharon Lewin's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Dramatic Rise in Plasma Viremia after CD8+ T Cell Depletion in Simian Immunodeficiency Virus–infected Macaques (1999) (1546)
- The end of AIDS: HIV infection as a chronic disease (2013) (1455)
- Plasma levels of soluble CD14 independently predict mortality in HIV infection. (2011) (983)
- Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19 (2020) (927)
- Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. (1999) (848)
- HIV infection: epidemiology, pathogenesis, treatment, and prevention (2014) (690)
- Towards an HIV cure: a global scientific strategy (2012) (520)
- Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial. (2014) (506)
- Activation of HIV Transcription with Short-Course Vorinostat in HIV-Infected Patients on Suppressive Antiretroviral Therapy (2014) (428)
- Serum hepatitis B surface antigen and hepatitis B e antigen titers: Disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers (2010) (399)
- Measuring Recent Thymic Emigrants in Blood of Normal and HIV-1–Infected Individuals before and after Effective Therapy (1999) (372)
- International AIDS Society global scientific strategy: towards an HIV cure 2016 (2016) (372)
- An In-Depth Comparison of Latent HIV-1 Reactivation in Multiple Cell Model Systems and Resting CD4+ T Cells from Aviremic Patients (2013) (358)
- The CD16+ Monocyte Subset Is More Permissive to Infection and Preferentially Harbors HIV-1 In Vivo1 (2007) (347)
- Regulation of Toll‐like receptor‐2 expression in chronic hepatitis B by the precore protein (2007) (346)
- CXCR5+ follicular cytotoxic T cells control viral infection in B cell follicles (2016) (340)
- Immune checkpoint blockade in infectious diseases (2017) (328)
- CD4+ T Cells Expressing PD-1, TIGIT and LAG-3 Contribute to HIV Persistence during ART (2016) (306)
- Isolation and rapid sharing of the 2019 novel coronavirus (SARS‐CoV‐2) from the first patient diagnosed with COVID‐19 in Australia (2020) (280)
- Use of Real-Time PCR and Molecular Beacons To Detect Virus Replication in Human Immunodeficiency Virus Type 1-Infected Individuals on Prolonged Effective Antiretroviral Therapy (1999) (259)
- Getting the "Kill" into "Shock and Kill": Strategies to Eliminate Latent HIV. (2018) (241)
- Analysis of hepatitis B viral load decline under potent therapy: Complex decay profiles observed (2001) (227)
- CCR7 ligands CCL19 and CCL21 increase permissiveness of resting memory CD4+ T cells to HIV-1 infection: a novel model of HIV-1 latency. (2007) (221)
- Establishment of HIV-1 latency in resting CD4+ T cells depends on chemokine-induced changes in the actin cytoskeleton (2010) (218)
- Normal T-Cell Turnover in Sooty Mangabeys Harboring Active Simian Immunodeficiency Virus Infection (2000) (215)
- Advancing global health and strengthening the HIV response in the era of the Sustainable Development Goals: the International AIDS Society—Lancet Commission (2018) (193)
- Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy (2006) (186)
- Direct evidence for new T-cell generation by patients after either T-cell-depleted or unmodified allogeneic hematopoietic stem cell transplantations. (2002) (182)
- Short-term administration of disulfiram for reversal of latent HIV infection: a phase 2 dose-escalation study. (2015) (178)
- Pharmacy adherence measures to assess adherence to antiretroviral therapy: review of the literature and implications for treatment monitoring. (2011) (163)
- HIV-hepatitis B virus coinfection: epidemiology, pathogenesis, and treatment (2017) (159)
- Restoration of replication phenotype of lamivudine-resistant hepatitis B virus mutants by compensatory changes in the "fingers" subdomain of the viral polymerase selected as a consequence of mutations in the overlapping S gene. (2002) (138)
- A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naïve individuals in Thailand (2008) (135)
- Comparison of HDAC inhibitors in clinical development (2013) (134)
- HDAC inhibitors in HIV (2012) (130)
- Uncoupling coreceptor usage of human immunodeficiency virus type 1 (HIV-1) from macrophage tropism reveals biological properties of CCR5-restricted HIV-1 isolates from patients with acquired immunodeficiency syndrome. (2005) (130)
- HIV cure and eradication: how will we get from the laboratory to effective clinical trials? (2011) (130)
- Increased glucose metabolic activity is associated with CD4+ T-cell activation and depletion during chronic HIV infection (2014) (128)
- PD-1 blockade potentiates HIV latency reversal ex vivo in CD4+ T cells from ART-suppressed individuals (2019) (125)
- Biological determinants of immune reconstitution in HIV-infected patients receiving antiretroviral therapy: the role of interleukin 7 and interleukin 7 receptor α and microbial translocation. (2010) (123)
- HIV and co‐infections (2013) (121)
- Exposure to Dideoxynucleosides Is Reflected in Lowered Mitochondrial DNA in Subcutaneous Fat (2002) (119)
- Both CD31(+) and CD31⁻ naive CD4(+) T cells are persistent HIV type 1-infected reservoirs in individuals receiving antiretroviral therapy. (2010) (119)
- Shocking HIV out of hiding: where are we with clinical trials of latency reversing agents? (2016) (116)
- Effect of ipilimumab on the HIV reservoir in an HIV-infected individual with metastatic melanoma. (2015) (116)
- Inhibition of telomerase activity by human immunodeficiency virus (HIV) nucleos(t)ide reverse transcriptase inhibitors: a potential factor contributing to HIV-associated accelerated aging. (2013) (115)
- Ten years of highly active antiretroviral therapy for HIV infection (2007) (115)
- Programmed cell death-1 contributes to the establishment and maintenance of HIV-1 latency (2018) (111)
- Virologically Suppressed HIV Patients Show Activation of NK Cells and Persistent Innate Immune Activation (2012) (106)
- Differential Expression of CD163 on Monocyte Subsets in Healthy and HIV-1 Infected Individuals (2011) (106)
- Naive T cells are maintained by thymic output in early ages but by proliferation without phenotypic change after age twenty (2003) (106)
- CD4+ T-cell deficiency in HIV patients responding to antiretroviral therapy is associated with increased expression of interferon-stimulated genes in CD4+ T cells. (2011) (102)
- Identification of Lineage Relationships and Novel Markers of Blood and Skin Human Dendritic Cells (2013) (100)
- Paraneoplastic myasthenia gravis correlates with generation of mature naive CD4(+) T cells in thymomas. (2002) (99)
- Endosomal NOX2 oxidase exacerbates virus pathogenicity and is a target for antiviral therapy (2017) (98)
- Clinical and mycological predictors of cryptococcosis-associated immune reconstitution inflammatory syndrome (2013) (97)
- Expression and reactivation of HIV in a chemokine induced model of HIV latency in primary resting CD4+ T cells (2011) (96)
- Integrated immune dynamics define correlates of COVID-19 severity and antibody responses (2020) (96)
- Barriers and strategies to achieve a cure for HIV. (2018) (95)
- HIV Reactivation from Latency after Treatment Interruption Occurs on Average Every 5-8 Days—Implications for HIV Remission (2015) (93)
- Immunopathogenesis of hepatic flare in HIV/hepatitis B virus (HBV)-coinfected individuals after the initiation of HBV-active antiretroviral therapy. (2009) (91)
- Persistent immune activation in chronic HIV infection: do any interventions work? (2013) (90)
- A Systematic Review of T-cell Epitopes in Hepatitis B Virus: Identification, Genotypic Variation and Relevance to Antiviral Therapeutics (2008) (88)
- Clinical and virological predictors of hepatic flares in pregnant women with chronic hepatitis B (2014) (86)
- Splenectomy Associated Changes in IgM Memory B Cells in an Adult Spleen Registry Cohort (2011) (86)
- Paediatric HIV infection: the potential for cure (2016) (85)
- Ongoing Clinical Trials of Human Immunodeficiency Virus Latency-Reversing and Immunomodulatory Agents (2016) (81)
- HIV-1 Escape from the CCR5 Antagonist Maraviroc Associated with an Altered and Less-Efficient Mechanism of gp120-CCR5 Engagement That Attenuates Macrophage Tropism (2011) (81)
- Research priorities for an HIV cure: International AIDS Society Global Scientific Strategy 2021 (2021) (78)
- Research priorities for an HIV cure: International AIDS Society Global Scientific Strategy 2021 (2021) (78)
- Reduced Hepatitis B Virus (HBV)-Specific CD4+ T-Cell Responses in Human Immunodeficiency Virus Type 1-HBV-Coinfected Individuals Receiving HBV-Active Antiretroviral Therapy (2005) (77)
- Patterns and causes of suboptimal response to tenofovir-based therapy in individuals coinfected with HIV and hepatitis B virus. (2013) (75)
- Pathogenicity and immunogenicity of attenuated, nef-deleted HIV-1 strains in vivo (2007) (75)
- HIV-1 Down-Modulates γ Signaling Chain of FcγR in Human Macrophages: A Possible Mechanism for Inhibition of Phagocytosis1 (2002) (75)
- HIV‐1 DNA and mRNA concentrations are similar in peripheral blood monocytes and alveolar macrophages in HIV‐1‐infected individuals (1998) (72)
- Functional cure of HIV: the scale of the challenge (2018) (72)
- Immune Restoration Diseases Reflect Diverse Immunopathological Mechanisms (2009) (71)
- Quantification of mitochondrial DNA in peripheral blood mononuclear cells and subcutaneous fat using real-time polymerase chain reaction. (2001) (70)
- Immunopathogenesis of hepatitis B virus infection (2007) (69)
- HIV-1 cell entry and advances in viral entry inhibitor therapy. (2003) (68)
- The search for an HIV cure: tackling latent infection. (2013) (68)
- Chemokine levels and chemokine receptor expression in the blood and the cerebrospinal fluid of HIV-infected patients with cryptococcal meningitis and cryptococcosis-associated immune reconstitution inflammatory syndrome. (2013) (67)
- Surface CD4 is critical to in vitro HIV infection of human alveolar macrophages. (1996) (66)
- Biomarkers of immune dysfunction following combination antiretroviral therapy for HIV infection. (2011) (66)
- Broad activation of latent HIV-1 in vivo (2016) (65)
- Entinostat is a histone deacetylase inhibitor selective for class 1 histone deacetylases and activates HIV production from latently infected primary T cells (2013) (65)
- Persistence of integrated HIV DNA in CXCR3 + CCR6 + memory CD4+ T cells in HIV-infected individuals on antiretroviral therapy (2016) (65)
- Prevalence and characterization of lamivudine-resistant hepatitis B virus mutations in HIV–HBV co-infected individuals (2003) (65)
- Human immunodeficiency virus infection and the liver. (2012) (64)
- Altering cell death pathways as an approach to cure HIV infection (2013) (64)
- Comparison of HDAC inhibitors in clinical development Effect on HIV production in latently infected cells and T-cell activation (2013) (64)
- A common mechanism of clinical HIV-1 resistance to the CCR5 antagonist maraviroc despite divergent resistance levels and lack of common gp120 resistance mutations (2013) (62)
- Associations between surface markers on blood monocytes and carotid atherosclerosis in HIV‐positive individuals (2014) (62)
- HIV Reservoirs and Strategies for Eradication (2012) (61)
- Direct evidence for new T-cell generation by patients after either T-cell–depleted or unmodified allogeneic hematopoietic stem cell transplantationsPresented in part in abstract form at the 42nd Annual Meeting of the American Society of Hematology, San Francisco, CA, December 2000. (2002) (61)
- Myeloid Dendritic Cells Induce HIV-1 Latency in Non-proliferating CD4+ T Cells (2010) (61)
- Graves' disease during immune reconstitution after highly active antiretroviral therapy for HIV infection: evidence of thymic dysfunction. (2004) (60)
- Combination HBV therapy is linked to greater HBV DNA suppression in a cohort of lamivudine-experienced HIV/HBV coinfected individuals (2009) (59)
- Intensification of antiretroviral therapy with raltegravir or addition of hyperimmune bovine colostrum in HIV-infected patients with suboptimal CD4+ T-cell response: a randomized controlled trial. (2011) (58)
- Hepatitis B treatment: rational combination chemotherapy based on viral kinetic and animal model studies. (2002) (56)
- Dynamics of T Cells and TCR Excision Circles Differ After Treatment of Acute and Chronic HIV Infection1 2 (2002) (55)
- HIV integration sites in latently infected cell lines: evidence of ongoing replication (2017) (55)
- Human Immunodeficiency Virus Persistence and T-Cell Activation in Blood, Rectal, and Lymph Node Tissue in Human Immunodeficiency Virus–Infected Individuals Receiving Suppressive Antiretroviral Therapy (2017) (55)
- Identifying Cytomegalovirus Complications Using the Quantiferon-CMV Assay After Allogeneic Hematopoietic Stem Cell Transplantation (2017) (54)
- Impact of antiretroviral therapy (ART) timing on chronic immune activation/inflammation and end-organ damage (2015) (54)
- Metabolically active CD4+ T cells expressing Glut1 and OX40 preferentially harbor HIV during in vitro infection (2017) (54)
- The phenotype of hepatitis B virus–specific T cells differ in the liver and blood in chronic hepatitis B virus infection (2007) (53)
- HIV-1 down-modulates gamma signaling chain of Fc gamma R in human macrophages: a possible mechanism for inhibition of phagocytosis. (2002) (53)
- Sex-Based Differences in Human Immunodeficiency Virus Type 1 Reservoir Activity and Residual Immune Activation (2018) (53)
- Increased intrahepatic apoptosis but reduced immune activation in HIV-HBV co-infected patients with advanced immunosuppression (2011) (50)
- Finding a cure for HIV: will it ever be achievable? (2011) (50)
- Evaluation of Serological Tests for SARS-CoV-2: Implications for Serology Testing in a Low-Prevalence Setting (2020) (49)
- Effects of HIV‐1 infection in vitro on transendothelial migration by monocytes and monocyte‐derived macrophages (2009) (49)
- Enrichment of gut-derived Fusobacterium is associated with suboptimal immune recovery in HIV-infected individuals (2018) (49)
- Coinfection of Hepatic Cell Lines with Human Immunodeficiency Virus and Hepatitis B Virus Leads to an Increase in Intracellular Hepatitis B Surface Antigen (2010) (49)
- Modeling the Effects of Vorinostat In Vivo Reveals both Transient and Delayed HIV Transcriptional Activation and Minimal Killing of Latently Infected Cells (2015) (49)
- Biomarkers of inflammation and coagulation are associated with mortality and hepatitis flares in persons coinfected with HIV and hepatitis viruses. (2013) (47)
- Cryptococcosis-IRIS is associated with lower cryptococcus-specific IFN-γ responses before antiretroviral therapy but not higher T-cell responses during therapy. (2013) (47)
- Novel Sensitive Real-Time PCR for Quantification of Bacterial 16S rRNA Genes in Plasma of HIV-Infected Patients as a Marker for Microbial Translocation (2011) (46)
- The testis and epididymis are productively infected by SIV and SHIV in juvenile macaques during the post-acute stage of infection (2007) (46)
- Hepatitis B and Delta Virus Are Prevalent but Often Subclinical Co-Infections among HIV Infected Patients in Guinea-Bissau, West Africa: A Cross-Sectional Study (2014) (45)
- Cytomegalovirus Reactivation Is Associated with Increased Risk of Late-Onset Invasive Fungal Disease after Allogeneic Hematopoietic Stem Cell Transplantation: A Multicenter Study in the Current Era of Viral Load Monitoring. (2017) (45)
- The anti-HIV activity of entecavir: a multicentre evaluation of lamivudine-experienced and lamivudine-naive patients (2008) (45)
- Between a shock and a hard place: challenges and developments in HIV latency reversal. (2019) (44)
- Preferential Infection of Dendritic Cells during Human Immunodeficiency Virus Type 1 Infection of Blood Leukocytes (2006) (44)
- HIV-1 predisposed to acquiring resistance to maraviroc (MVC) and other CCR5 antagonists in vitro has an inherent, low-level ability to utilize MVC-bound CCR5 for entry (2011) (44)
- Balamuthia mandrillaris brain abscess successfully treated with complete surgical excision and prolonged combination antimicrobial therapy. (2011) (44)
- Impact of Early Viral Kinetics on T-Cell Reactivity during Antiviral Therapy in Chronic Hepatitis B (2007) (44)
- Identification of a novel hepatitis B virus precore/core deletion mutant in HIV/hepatitis B virus co-infected individuals (2007) (43)
- Immunopathogenesis: role of innate and adaptive immune responses. (2006) (43)
- The novel histone deacetylase inhibitors metacept-1 and metacept-3 potently increase HIV-1 transcription in latently infected cells (2009) (43)
- Changes in mitochondrial DNA in peripheral blood mononuclear cells from HIV-infected patients with lipoatrophy randomized to receive abacavir. (2004) (43)
- Immune Monitoring for CMV in Transplantation (2018) (42)
- Viral Adaptation to Host Immune Responses Occurs in Chronic Hepatitis B Virus (HBV) Infection, and Adaptation Is Greatest in HBV e Antigen-Negative Disease (2011) (41)
- Quantitative HBsAg and HBeAg Predict Hepatitis B Seroconversion after Initiation of HAART in HIV-HBV Coinfected Individuals (2013) (41)
- Impaired Quality of the Hepatitis B Virus (HBV)-Specific T-Cell Response in Human Immunodeficiency Virus Type 1-HBV Coinfection (2009) (41)
- Consensus statement on the role of health systems in advancing the long-term well-being of people living with HIV (2021) (39)
- Constitutive expression of p50 homodimer in freshly isolated human monocytes decreases with in vitro and in vivo differentiation: a possible mechanism influencing human immunodeficiency virus replication in monocytes and mature macrophages (1997) (39)
- HIV‐1 envelope–receptor interactions required for macrophage infection and implications for current HIV‐1 cure strategies (2014) (37)
- Virologic Determinants of Success After Structured Treatment Interruptions of Antiretrovirals in Acute HIV-1 Infection (2008) (36)
- A new way of measuring apoptosis by absolute quantitation of inter-nucleosomally fragmented genomic DNA (2012) (35)
- Clinical Predictors of Immune Reconstitution following Combination Antiretroviral Therapy in Patients from the Australian HIV Observational Database (2011) (34)
- A randomised controlled trial of oral zinc on the immune response to tuberculosis in HIV-infected patients. (2005) (34)
- The kinetics of surface expression of CD11/CD18 integrins and CD54 on monocytes and macrophages (1995) (33)
- Multi-site assessment of rapid, point-of-care antigen testing for the diagnosis of SARS-CoV-2 infection in a low-prevalence setting: A validation and implementation study (2021) (33)
- Efficacy of tenofovir disoproxil fumarate/ emtricitabine compared with emtricitabine alone in antiretroviral-naive HIV–HBV coinfection in Thailand (2010) (33)
- HBV mutations in untreated HIV-HBV co-infection using genomic length sequencing. (2010) (32)
- Perceptions of HIV cure research among people living with HIV in Australia (2018) (32)
- Towards a cure for HIV—are we making progress? (2014) (32)
- Lipopolysaccharide, immune activation, and liver abnormalities in HIV/hepatitis B virus (HBV)-coinfected individuals receiving HBV-active combination antiretroviral therapy. (2014) (31)
- Targeting antigen to bone marrow stromal cell‐2 expressed by conventional and plasmacytoid dendritic cells elicits efficient antigen presentation (2013) (31)
- Ex Vivo Response to Histone Deacetylase (HDAC) Inhibitors of the HIV Long Terminal Repeat (LTR) Derived from HIV-Infected Patients on Antiretroviral Therapy (2014) (31)
- Chronic Hepatitis B Infection and Pregnancy (2012) (31)
- The role of naïve T-cells in HIV-1 pathogenesis: an emerging key player. (2011) (30)
- In Vivo T Cell-Targeting Nanoparticle Drug Delivery Systems: Considerations for Rational Design. (2021) (30)
- The role of SNPs in the α-chain of the IL-7R gene in CD4+ T-cell recovery in HIV-infected African patients receiving suppressive cART (2011) (30)
- CNS-specific regulatory elements in brain-derived HIV-1 strains affect responses to latency-reversing agents with implications for cure strategies (2015) (30)
- Combination Immune Checkpoint Blockade to Reverse HIV Latency (2020) (30)
- Age‐dependent changes in T cell homeostasis and SIV load in sooty mangabeys (2000) (29)
- The case for an HIV cure and how to get there (2020) (29)
- The role of antigen presenting cells in the induction of HIV-1 latency in resting CD4+ T-cells (2015) (29)
- Thymic function in severely immunodeficient HIV type 1-infected patients receiving stable and effective antiretroviral therapy. (2006) (29)
- Impact of Allogeneic Hematopoietic Stem Cell Transplantation on the HIV Reservoir and Immune Response in 3 HIV-Infected Individuals (2017) (29)
- A Cure for HIV Infection: “Not in My Lifetime” or “Just Around the Corner”? (2016) (29)
- Thymic plasmacytoid dendritic cells are susceptible to productive HIV-1 infection and efficiently transfer R5 HIV-1 to thymocytes in vitro (2011) (29)
- HIV inhibits early signal transduction events triggered by CD16 cross‐linking on NK cells, which are important for antibody‐dependent cellular cytotoxicity (2011) (28)
- Human Immunodeficiency Virus (HIV)–Infected CCR6+ Rectal CD4+ T Cells and HIV Persistence On Antiretroviral Therapy (2019) (28)
- Anti-HIV Antibody Responses and the HIV Reservoir Size during Antiretroviral Therapy (2016) (28)
- The effect of antiretroviral intensification with dolutegravir on residual virus replication in HIV-infected individuals: a randomised, placebo-controlled, double-blind trial. (2018) (28)
- Toxicity and in vitro activity of HIV-1 latency-reversing agents in primary CNS cells (2016) (27)
- The Sydney Declaration: a call to scale up research (2007) (27)
- Major health impact of accelerated aging in young HIV-infected individuals on antiretroviral therapy (2017) (27)
- Reprogrammed CRISPR-Cas13b suppresses SARS-CoV-2 replication and circumvents its mutational escape through mismatch tolerance (2020) (27)
- Diverse effects of interferon alpha on the establishment and reversal of HIV latency (2020) (27)
- Defective hepatitis B virus DNA is not associated with disease status but is reduced by polymerase mutations associated with drug resistance (2008) (26)
- Assessment of HBV flare in a randomized clinical trial in HIV/HBV coinfected subjects initiating HBV-active antiretroviral therapy in Thailand (2012) (26)
- A cautionary tale: fatal lactic acidosis complicating nucleoside analogue and metformin therapy. (2003) (25)
- HIV integration sites and implications for maintenance of the reservoir (2017) (25)
- Enhanced Replicative Capacity and Pathogenicity of HIV-1 Isolated From Individuals Infected With Drug-Resistant Virus and Declining CD4+ T-Cell Counts (2005) (25)
- HIV latency reversing agents act through Tat post translational modifications (2018) (24)
- Comparison of Sequence Analysis and a Novel Discriminatory Real-Time PCR Assay for Detection and Quantification of Lamivudine-Resistant Hepatitis B Virus Strains (2004) (24)
- HIV integration and the establishment of latency in CCL19-treated resting CD4+ T cells require activation of NF-κB (2016) (24)
- The Pathway To Establishing HIV Latency Is Critical to How Latency Is Maintained and Reversed (2018) (23)
- Experiences and expectations of participants completing an HIV cure focused clinical trial. (2015) (23)
- Viral dynamics of hepatitis B virus DNA in human immunodeficiency virus‐1–hepatitis B virus coinfected individuals: Similar effectiveness of lamivudine, tenofovir, or combination therapy (2009) (23)
- Plasmacytoid dendritic cells sense HIV replication before detectable viremia following treatment interruption. (2020) (23)
- Multi-stakeholder consensus on a target product profile for an HIV cure (2020) (23)
- The pathogenesis of liver disease in the setting of HIV–hepatitis B virus coinfection (2009) (23)
- Association Between Plasma Antibody Responses and Risk for Cryptococcus-Associated Immune Reconstitution Inflammatory Syndrome (2018) (23)
- Clinical trials of antiretroviral treatment interruption in HIV-infected individuals (2019) (22)
- A Possible Sterilizing Cure of HIV-1 Infection Without Stem Cell Transplantation (2021) (22)
- Relative significance of different pathways of immune reconstitution in HIV type 1 infection as estimated by mathematical modeling. (2001) (22)
- The magnitude of HIV-1 resistance to the CCR5 antagonist maraviroc may impart a differential alteration in HIV-1 tropism for macrophages and T-cell subsets. (2013) (22)
- Impact of anti-PD-1 and anti-CTLA-4 on the HIV reservoir in people living with HIV with cancer on antiretroviral therapy: The AIDS Malignancy Consortium-095 study. (2021) (22)
- No Increase in Hepatitis B Virus (HBV)-Specific CD8+ T Cells in Patients with HIV-1-HBV Coinfections following HBV-Active Highly Active Antiretroviral Therapy (2010) (21)
- Modeling of Experimental Data Supports HIV Reactivation from Latency after Treatment Interruption on Average Once Every 5–8 Days (2016) (21)
- Immunological and virological failure after antiretroviral therapy is associated with enhanced peripheral and thymic pathogenicity. (2003) (21)
- Population Pharmacokinetics and Pharmacodynamics of Disulfiram on Inducing Latent HIV‐1 Transcription in a Phase IIb Trial (2018) (21)
- HIV persistence and T-cell activation in blood, rectal and lymph node tissue in HIV-infected individuals receiving suppressive ART. (2017) (21)
- Effects of long-term tenofovir-based combination antiretroviral therapy in HIV-hepatitis B virus coinfection on persistent hepatitis B virus viremia and the role of hepatitis B virus quasispecies diversity (2016) (20)
- Intrahepatic CXCL10 is strongly associated with liver fibrosis in HIV-Hepatitis B co-infection (2020) (20)
- Substantial Improvements in Performance Indicators Achieved in a Peripheral Blood Mononuclear Cell Cryopreservation Quality Assurance Program Using Single Donor Samples (2006) (20)
- The CD 16 Monocyte Subset Is More Permissive to Infection and Preferentially Harbors HIV-1 In Vivo 1 (2007) (20)
- Pharmacy and Self-Report Adherence Measures to Predict Virological Outcomes for Patients on Free Antiretroviral Therapy in Tamil Nadu, India (2013) (19)
- Compartmentalization of innate immune responses in the central nervous system during cryptococcal meningitis/HIV coinfection (2014) (19)
- Decreased NK Cell FcRγ in HIV-1 Infected Individuals Receiving Combination Antiretroviral Therapy: a Cross Sectional Study (2010) (19)
- Relationship between CD4 T cell turnover, cellular differentiation and HIV persistence during ART (2021) (19)
- Human cytomegalovirus (CMV)-specific CD8+ T cell responses are reduced in HIV-infected individuals with a history of CMV disease despite CD4+ T cell recovery. (2007) (19)
- The “work” of women when considering and using interventions to reduce mother-to-child transmission (MTCT) of HIV (2009) (19)
- Relationship between Measures of HIV Reactivation and Decline of the Latent Reservoir under Latency-Reversing Agents (2017) (19)
- Hepatitis virus immune restoration disease of the liver (2008) (18)
- Ethics of ART interruption after stem-cell transplantation. (2016) (18)
- Fatal acute varicella-zoster virus hemorrhagic meningomyelitis with necrotizing vasculitis in an HIV-infected patient. (2009) (18)
- Hepatitis C prevalence among HIV-infected patients in Guinea-Bissau: a descriptive cross-sectional study. (2014) (18)
- HIV persistence: chemokines and their signalling pathways. (2012) (18)
- Variation in cell-associated unspliced HIV RNA on antiretroviral therapy is associated with the circadian regulator brain-and-muscle-ARNT-like-1 (2018) (18)
- Circulating Heat Shock Protein 60 Levels Are Elevated in HIV Patients and Are Reduced by Anti-Retroviral Therapy (2012) (18)
- HIV Infection and TLR Signalling in the Liver (2012) (17)
- HIV Management in Australasia: A Guide for Clinical Care (2009) (17)
- Liver Fibrosis Regression Measured by Transient Elastography in Human Immunodeficiency Virus (HIV)-Hepatitis B Virus (HBV)-Coinfected Individuals on Long-Term HBV-Active Combination Antiretroviral Therapy (2016) (17)
- The end of HIV: Still a very long way to go, but progress continues (2017) (17)
- A gathering storm: HIV infection and nonalcoholic fatty liver disease in low and middle-income countries (2019) (17)
- Plasma But Not Cerebrospinal Fluid Interleukin 7 and Interleukin 5 Levels Pre-Antiretroviral Therapy Commencement Predict Cryptococcosis-Associated Immune Reconstitution Inflammatory Syndrome. (2017) (17)
- Immunity in young adult survivors of childhood leukemia is similar to the elderly rather than age‐matched controls: Role of cytomegalovirus (2016) (17)
- Cancer therapies in HIV cure research (2017) (16)
- Is specific HIV eradication from the brain possible or needed? (2013) (16)
- Incidence of putative HIV superinfection and sexual practices among HIV-infected men who have sex with men. (2008) (16)
- Multiply spliced HIV RNA is a predictive measure of virus production ex vivo and in vivo following reversal of HIV latency (2021) (16)
- Pembrolizumab induces HIV latency reversal in people living with HIV and cancer on antiretroviral therapy (2022) (16)
- Perspectives on Analytical Treatment Interruptions in People Living with HIV and Their Health Care Providers in the Landscape of HIV Cure-Focused Studies (2019) (15)
- Evaluation of 6 Commercial SARS-CoV-2 Serology Assays Detecting Different Antibodies for Clinical Testing and Serosurveillance (2021) (15)
- The role of bronchoscopy in the diagnosis and treatment of pulmonary disease in HIV-infected patients. (1995) (15)
- Ethics and hepatitis B cure research (2016) (15)
- Antibody and B-cell responses may control circulating lipopolysaccharide in patients with HIV infection (2011) (15)
- PD-1 Expression in HIV-Specific CD8+ T cells Before Antiretroviral Therapy Is Associated With HIV Persistence (2019) (15)
- A randomized trial of vorinostat with treatment interruption after initiating antiretroviral therapy during acute HIV-1 infection (2020) (15)
- A randomized trial of vorinostat with treatment interruption after initiating antiretroviral therapy during acute HIV-1 infection (2020) (15)
- A randomized trial of vorinostat with treatment interruption after initiating antiretroviral therapy during acute HIV-1 infection (2020) (15)
- A cure for HIV: where we've been, and where we're headed (2013) (14)
- Comparison of Real-Time PCR Assays for Monitoring Serum Hepatitis B Virus DNA Levels during Antiviral Therapy (2006) (14)
- Human thymic dendritic cells: regulators of T cell development in health and HIV-1 infection. (2008) (14)
- The significance and expectations of HIV cure research among people living with HIV in Australia (2020) (14)
- Long-Term TDF-Inclusive ART and Progressive Rates of HBsAg Loss in HIV-HBV Coinfection-Lessons for Functional HBV Cure? (2020) (14)
- Suppurative thyroiditis due to Nocardia asteroides. (1993) (14)
- Comparison of Etests and Vitek 2 ® to broth microdilution for the susceptibility testing of Cryptococcus neoformans. (2014) (14)
- CXCR4-Using HIV Strains Predominate in Naive and Central Memory CD4+ T Cells in People Living with HIV on Antiretroviral Therapy: Implications for How Latency Is Established and Maintained (2019) (14)
- Post-treatment control in an adult with perinatally acquired HIV following cessation of antiretroviral therapy. (2017) (14)
- HIV replication is associated with increased severity of liver biopsy changes in HIV‐HBV and HIV‐HCV co‐infection (2012) (13)
- No Difference in the Rate of Change in Telomere Length or Telomerase Activity in HIV-Infected Patients after Three Years of Darunavir/Ritonavir with and without Nucleoside Analogues in the MONET Trial (2014) (13)
- Myeloid Dendritic Cells Induce HIV Latency in Proliferating CD4+ T Cells (2018) (13)
- Early Events of HIV-1 Infection: Can Signaling be the Next Therapeutic Target? (2011) (13)
- HealthMap: a cluster randomised trial of interactive health plans and self-management support to prevent coronary heart disease in people with HIV (2016) (13)
- Modeling of Antilatency Treatment in HIV: What Is the Optimal Duration of Antiretroviral Therapy-Free HIV Remission? (2017) (12)
- Kick and kill for HIV latency (2020) (12)
- Preliminary assessment of Treponema pallidum-specific IgM antibody detection and a new rapid point-of-care assay for the diagnosis of syphilis in human immunodeficiency virus-1-infected patients (2010) (12)
- Low T-Cell Responses to Mitogen Stimulation Predicts Poor Survival in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation (2017) (12)
- Correction: HIV Reactivation from Latency after Treatment Interruption Occurs on Average Every 5-8 Days—Implications for HIV Remission (2016) (12)
- Relationship of Human Immunodeficiency Virus Viral Load in Cerebrospinal Fluid and Plasma in Patients Co-infected With Cryptococcal Meningitis (2017) (12)
- Breadth of concomitant immune responses underpinning viral clearance and patient recovery in a non-severe case of COVID-19 (2020) (12)
- Factors Associated with Elevated ALT in an International HIV/HBV Co-Infected Cohort on Long-Term HAART (2011) (12)
- Short communication: CD4 T cell declines occurring during suppressive antiretroviral therapy reflect continued production of Casp8p41. (2014) (11)
- Identifying Key Drivers of the Impact of an HIV Cure Intervention in Sub-Saharan Africa (2016) (11)
- The CD14 C-260T single nucleotide polymorphism (SNP) modulates monocyte/macrophage activation in treated HIV-infected individuals (2015) (11)
- Identification of 5-Substituted 2-Acylaminothiazoles That Activate Tat-Mediated Transcription in HIV-1 Latency Models. (2019) (10)
- Polymorphisms in the CD14 and TLR4 genes independently predict CD4+ T-cell recovery in HIV-infected individuals on antiretroviral therapy (2016) (10)
- A novel, rapid method to detect infectious HIV-1 from plasma of persons infected with HIV-1. (2010) (10)
- Severe hepatitis and prolonged hepatitis B virus-specific CD8 T-cell response after selection of hepatitis B virus YMDD variant in an HIV/hepatitis B virus-co-infected patient (2004) (10)
- HIV and aging: an overview of an emerging issue. (2011) (10)
- In vitro replication phenotype of a novel (−1G) hepatitis B virus variant associated with HIV co‐infection (2012) (10)
- Variable uptake of recommended interventions to reduce mother‐to‐child transmission of HIV in Australia, 1982–2005 (2008) (10)
- Hepatitis C Virus (HCV) Clearance After Treatment With Direct-Acting Antivirals in Human Immunodeficiency Virus (HIV)-HCV Coinfection Modulates Systemic Immune Activation and HIV Transcription on Antiretroviral Therapy (2020) (10)
- Tat IRES modulator of tat mRNA (TIM-TAM): a conserved RNA structure that controls Tat expression and acts as a switch for HIV productive and latent infection (2019) (10)
- Cryptococcosis-Associated Immune Reconstitution Inflammatory Syndrome Is Associated With Dysregulation of IL-7/IL-7 Receptor Signaling Pathway in T Cells and Monocyte Activation (2019) (9)
- Molecular Gymnastics: Mechanisms of HIV-1 Resistance to CCR5 Antagonists and Impact on Virus Phenotypes. (2015) (9)
- Intact HIV Proviruses Persist in the Brain Despite Viral Suppression with ART (2022) (9)
- A Phase I Study of the Pharmacokinetics and Safety of Passive Immunotherapy with Caprine Anti-HIV Antibodies, PEHRG214, in HIV-1--Infected Individuals (2004) (9)
- No adverse safety or virological changes 2 years following vorinostat in HIV-infected individuals on antiretroviral therapy (2017) (9)
- 2018 international meeting of the Global Virus Network (2019) (9)
- A clinical trial of non-invasive imaging with an anti-HIV antibody labelled with copper-64 in people living with HIV and uninfected controls (2021) (9)
- Strategies for an HIV cure: progress and challenges (2018) (9)
- Future directions in the treatment of HIV-HBV coinfection. (2009) (9)
- Combination Immune Checkpoint Blockade Enhances IL-2 and CD107a Production from HIV-Specific T Cells Ex Vivo in People Living with HIV on Antiretroviral Therapy (2021) (9)
- Sex-Based Differences in HIV-1 Reservoir Activity and Residual Immune Activation. (2018) (8)
- Analysis of Clinical HIV-1 Strains with Resistance to Maraviroc Reveals Strain-Specific Resistance Mutations, Variable Degrees of Resistance, and Minimal Cross-Resistance to Other CCR5 Antagonists. (2017) (8)
- Understanding Factors That Modulate the Establishment of HIV Latency in Resting CD4+ T-Cells In Vitro (2016) (8)
- The evidence for a change in antenatal HIV screening policy in Australia (2006) (8)
- Decline in Serum 25 Hydroxyvitamin D Levels in HIV–Hbv-Coinfected Patients after Long-Term Antiretroviral Therapy (2014) (8)
- Quantifying Adaptive and Innate Immune Responses in HIV-Infected Participants Using a Novel High Throughput Assay (2016) (8)
- A Randomized Controlled Trial of Lisinopril to Decrease Lymphoid Fibrosis in Antiretroviral-Treated, HIV-infected Individuals (2017) (8)
- Finding a Cure for HIV: Much Work to Do (2014) (7)
- Impact of alemtuzumab on HIV persistence in an HIV-infected individual on antiretroviral therapy with Sezary syndrome (2017) (7)
- Leveraging the advances in HIV for COVID-19 (2020) (7)
- The impact of immune checkpoint therapy on the latent reservoir in HIV infected individuals with cancer on antiretroviral therapy. (2021) (7)
- CD4- and Time-Dependent Susceptibility of HIV-1-Infected Cells to Antibody-Dependent Cellular Cytotoxicity (2019) (7)
- Immune recovery uveitis in an HIV‐negative individual † (2007) (7)
- Early experience with antimicrobial stewardship ward rounds at a tertiary referral hospital (2011) (7)
- HIV cure research in the time of COVID-19 - Antiretroviral therapy treatment interruption trials: A discussion paper (2020) (6)
- Sexual transmission of HIV and the law: an Australian medical consensus statement (2016) (6)
- What are the barriers to offering HIV testing in an antenatal setting? A national study of obstetricians (2007) (5)
- Community and provider Community and provider perspectives on Treatment Interruptions in the landscape of HIV cure focused studies. (2019) (5)
- A cure for HIV: how would we know? (2020) (5)
- Limitations of dual‐fluorescent HIV reporter viruses in a model of pre‐activation latency (2019) (5)
- Genetic polymorphisms in the CD14 gene are associated with monocyte activation and carotid intima-media thickness in HIV-infected patients on antiretroviral therapy (2016) (5)
- The RNA-Binding Proteins SRP14 and HMGB3 Control HIV-1 Tat mRNA Processing and Translation During HIV-1 Latency (2021) (5)
- Immune checkpoint blockade in HIV (2022) (5)
- Pneumocystis carinii pneumonia after cessation of secondary prophylaxis in a patient on highly active antiretroviral therapy with a CD4 cell count greater than 200/mm3. (2001) (5)
- Entry of HIV in primary human resting CD4(+) T cells pretreated with the chemokine CCL19. (2014) (5)
- Extremely prolonged HIV seroconversion associated with an MHC haplotype carrying disease susceptibility genes for antibody deficiency disorders. (2010) (5)
- Longitudinal evaluation of laboratory-based serological assays for SARS-CoV-2 antibody detection (2021) (5)
- Population pharmacokinetics of tenofovir in HIV/HBV co-infected patients. (2015) (5)
- 8th IAS Conference on HIV Pathogenesis, Treatment & Prevention 19–22 July 2015, Vancouver, Canada (2015) (5)
- 8th IAS Conference on HIV Pathogenesis, Treatment & Prevention 19–22 July 2015, Vancouver, Canada (2015) (5)
- CD4- and time-dependent susceptibility of HIV-1-infected cells to ADCC (2019) (4)
- Erratum: HIV infection: Epidemiology, pathogenesis, treatment, and prevention (Lancet (2014) 384 (258-71)) (2014) (4)
- Asian Pacific Association for Study of the Liver (APASL) (2003) (4)
- Modulation of the CCR5 Receptor/Ligand Axis by Seminal Plasma and the Utility of In Vitro versus In Vivo Models (2019) (4)
- Gender Differences in Emerging Infectious Diseases (2010) (4)
- CXCL-10, Interleukin-12 and Interleukin-21 are not Immunological Predictors of Hbeag Seroconversion in HIV-1–HBV Coinfection following HBV-Active Antiretroviral Therapy (2014) (4)
- CD 4 1 T-Cell Deficiency in HIV Patients Responding to Antiretroviral Therapy Is Associated With Increased Expression of Interferon-Stimulated Genes in CD 4 1 T Cells (2011) (4)
- Acceptability, motivation and the prospect of cure for people living with HIV and their healthcare providers in HIV cure-focused treatment interruption studies (2020) (4)
- Highly reproducible transient transfections for the study of hepatitis B virus replication based on an internal GFP reporter system. (2004) (4)
- Individuals with HIV-1 Subtype C Infection and Cryptococcal Meningitis Exhibit Viral Genetic Intermixing of HIV-1 Between Plasma and Cerebrospinal Fluid and a High Prevalence of CXCR4-Using Variants. (2018) (4)
- Targets for intervention to improve virological outcomes for patients receiving free antiretroviral therapy in Tamil Nadu, India (2014) (4)
- HIV latency can be established in proliferating and nonproliferating resting CD4+ T cells in vitro: implications for latency reversal (2019) (4)
- TRAILshort Protects against CD4 T Cell Death during Acute HIV Infection (2019) (4)
- Circulating BAFF and CXCL10 levels predict response to pegylated interferon in patients with HBeAg-positive chronic hepatitis B. (2019) (4)
- PD-1 blockade potentiates HIV latency reversal ex vivo in CD4+ T cells from ART-suppressed individuals (2019) (3)
- Variable uptake of recommended interventions to reduce mother‐to‐child transmission of HIV in Australia, 1982–2005 (2009) (3)
- HIV cure research: print and online media reporting in Australia (2017) (3)
- Disseminated histoplasmosis: successful maintenance therapy with oral fluconazole. (1995) (3)
- Cell-associated HIV RNA has a Circadian Cycle in Males Living with HIV on Antiretroviral Therapy. (2021) (3)
- Erratum to: HIV integration sites in latently infected cell lines: evidence of ongoing replication (2017) (3)
- Sexually transmissible infection and HIV management among men who have sex with men with and without HIV: survey of medical practitioners who are members of the Australasian Society for HIV Medicine. (2008) (3)
- The purine nucleotide analogue LY582563 (mcc-478) inhibits replication of wild type and drug resistant hepatitis b virus (2002) (3)
- Statistical analysis of single-copy assays when some observations are zero (2019) (3)
- Nafamostat Mesylate for Treatment of COVID-19 in Hospitalised Patients: A Structured, Narrative Review (2022) (3)
- OA3-3 Anti-PD-1 disrupts HIV latency in non-proliferating but not in proliferating T cells (2017) (3)
- Markers of Immune Activation and Inflammation Are Associated with Higher Levels of Genetically-Intact HIV in HIV-HBV Co-Infected Individuals (2022) (3)
- Short-term Disulfiram to Reverse Latent HIV Infection: A Phase 2 Dose Escalation Study (2016) (3)
- Plasmacytoid DCs control HIV latency in resting T-cells by type I IFN alpha (2016) (2)
- Tesamorelin, liver fat, and NAFLD in the setting of HIV. (2019) (2)
- HIV persistence in the CNS: the final frontier for a cure? (2016) (2)
- OA3-5 LB Effect of vorinostat, hydroxychloroquine and maraviroc combination therapy on viremia following treatment interruption in individuals initiating ART during acute HIV infection (2016) (2)
- The role of latency reversal in HIV cure strategies (2022) (2)
- HIV DNA persists in hepatocytes in people with HIV-hepatitis B co-infection on antiretroviral therapy (2022) (2)
- Therapeutics for COVID-19: established and in development (2020) (2)
- Multiparameter immunohistochemistry analysis of HIV DNA, RNA and immune checkpoints in lymph node tissue. (2021) (2)
- Optimization of 5-substituted thiazolyl ureas and 6-substituted imidazopyridines as potential HIV-1 latency reversing agents. (2020) (2)
- Evaluation of six commercial SARS-CoV-2 Enzyme-Linked Immunosorbent assays for clinical testing and serosurveillance (2021) (2)
- Anticoagulation Strategies in Non–Critically Ill Patients with Covid-19 (2022) (2)
- The antiretroviral CCR5-inhibitor maraviroc effectively reverses HIV latency by phosphorylation of Nf-kappa B (2018) (2)
- Hepatitis B infection in people living with HIV - a global challenge needing more research. (2019) (2)
- [510] COMBINATION OF HBV-ACTIVE ANTIRETROVIRAL THERAPY INFLUENCES HBV VIROLOGICAL SUPPRESSION IN AN INTERNATIONAL COHORT OF 120 HIVHBV COINFECTED INDIVIDUALS (2007) (2)
- Neurotoxicity with high-dose disulfiram and vorinostat used for HIV latency reversal (2021) (2)
- Endosomal NOX2 oxidase exacerbates virus pathogenicity and is a target for antiviral therapy (2017) (2)
- Viral, inflammatory, and reservoir characteristics of posttreatment controllers (2021) (2)
- Is Australia prepared for the next pandemic? (2017) (2)
- Differential dynamics of donor DC and non-DC peripheral blood mononuclear cell microchimerism in lung transplantation. (2009) (2)
- Longitudinal analysis of subtype C envelope tropism for memory CD4+ T cell subsets over the first 3 years of untreated HIV-1 infection (2020) (2)
- CD4+ T cell signatures in HIV infection (2019) (2)
- Memory CD4+ T cells that co-express PD1 and CTLA4 have reduced response to activating stimuli facilitating HIV latency (2022) (2)
- infected individuals on long-term HBV-active cART (2016) (1)
- Immunity in young adult survivors of childhood leukemia is more similar to elderly rather than age-matched controls : Role of cytomegalovirus ( CMV ) (2016) (1)
- Soluble immune checkpoints as correlates for HIV persistence and T cell function in people with HIV on antiretroviral therapy (2023) (1)
- Treatment of hepatitis B virus (HBV) in the setting of HIV-HBV co-infection (2009) (1)
- HIV integration sites in latently infected cell lines: evidence of ongoing replication (2017) (1)
- HIV integration and the establishment of latency in CCL19-treated resting CD4+ T cells require activation of NF-κB (2016) (1)
- HIV Vaccines and Cure (2018) (1)
- SIV persists in lymphoid tissues despite alemtuzumab-induced CD4+ T cell depletion (2017) (1)
- Phase 1 single dose studies to optimize the pharmacokinetics of DG17, a novel HIV-protease inhibitor pro-drug, using sodium bicarbonate and ritonavir. (2008) (1)
- 33 Experiences and expectations of participants completing HIV cure-focused clinical trials (2017) (1)
- HIV latency reversing agents act through Tat post translational modifications (2018) (1)
- Broad immunity to SARS-CoV-2 variants of concern mediated by a SARS-CoV-2 receptor-binding domain protein vaccine (2022) (1)
- Antiretroviral Initiation at ≥800 CD4+ Cells/mm3 Associated With Lower Human Immunodeficiency Virus Reservoir Size (2022) (1)
- Balancing Statistical Power and Risk in HIV Cure Clinical Trial Design (2022) (1)
- Towards a cure for human immunodeficiency virus (2018) (1)
- HIV research in Australia: linking basic research findings with clinical and public health outcomes (2006) (1)
- Shock and kill within the CNS: A promising HIV eradication approach? (2022) (1)
- Clinical and virological factors that predict post partum flares in pregnant women with chronic HBV (2013) (1)
- Immunopathogenesis of HIV co-infections (2014) (1)
- Challenges, progress and strategies in the search for a cure for HIV (2014) (1)
- Outcomes following detection of low level plasma HIV RNA in HIV-infected patients previously virologically suppressed on antiretroviral therapy: a retrospective observational study. (2017) (1)
- Impact of anti-PD-1 and anti-CTLA-4 on the HIV reservoir in vivo: AMC-095 Study (2019) (1)
- Chapter 7 – Replication of Hepatitis B Virus and Pathogenesis of Disease (2006) (1)
- Comparison of Real-Time PCR Assays for Monitoring Serum Hepatitis B Virus DNA Levels during Antiretroviral Therapy (2007) (1)
- OP 2.5 – 00048 Targeting the SIV reservoir with Alemtuzumab (2022) (1)
- A Dynamic Interplay of Circulating Extracellular Vesicles and Galectin-1 Reprograms Viral Latency during HIV-1 Infection (2022) (1)
- Developing research priorities for Australia's response to infectious disease emergencies. (2017) (1)
- Intrahepatic CXCL-10 is strongly associated with markers of liver fibrosis in HIV-HBV co-infection (2016) (1)
- Editorial: HIV and lipopolysaccharide: double trouble in the liver (2017) (1)
- 1160 Analysis of early viral kinetics and T-cell reactivity in relation to HBEAG seroconversion during the first 12 weeks of antiviral therapy for chronic hepatitis B (2003) (1)
- Mitigation strategies to safely conduct HIV treatment research in the context of COVID‐19 (2022) (1)
- Hepatitis B virion (HBV) clearance is extremely rapid in a sub-set of chronically infected individuals (2001) (1)
- Enrichment of gut-derived Fusobacterium is associated with suboptimal immune recovery in HIV-infected individuals (2018) (1)
- Detection of Chimeric Cellular: HIV mRNAs Generated Through Aberrant Splicing in HIV-1 Latently Infected Resting CD4+ T Cells (2022) (1)
- The CD14 C-260T single nucleotide polymorphism (SNP) modulates monocyte/macrophage activation in treated HIV-infected individuals (2015) (1)
- The histone deacetylase inhibitors SAHA, MS-275, LBH589 and MCT3 are able to induce HIV-1 transcription with differing potencies in chronically infected cell lines and latently infected primary CD4( ) T-cells. (2010) (1)
- AIDS pathogenesis. (1994) (0)
- Experimental Quantification of Interactions Between Drug Delivery Systems and Cells In Vitro: A Guide for Preclinical Nanomedicine Evaluation. (2022) (0)
- De novo design of CRISPR-Cas13b enables efficient silencing of SARS-CoV-2 variants and tumour pathogenic RNAs with near single-base precision (2022) (0)
- HIV infection of hepatitis B virus (HBV)-infected hepatocytes increases CXCL10 production and is associated with liver fibrosis in HIV-HBV co-infected individuals (2019) (0)
- Our democracy and health crises: Reflections on the Australian response to HIV (2015) (0)
- Anticoagulation and Antiplatelet Strategies in Non-Critically Ill Patients with Covid-19 (2022) (0)
- Pustular skin lesions in a patient with advanced HIV infection and pneumonia. (2013) (0)
- Pro-fibrogenic role of alarmin high mobility group box 1 in HIV–hepatitis B virus coinfection (2022) (0)
- Virological characteristics of a longitudinal HIV/HBV co-infected cohort prior to initiation of HBV-active HAART (2008) (0)
- HCV treatment with direct-acting antivirals (DAAs) in HIV/HCV coinfected subjects affects the dynamics of the HIV-1 reservoir (2018) (0)
- Combination treatment prevents HIV re-emergence in monkeys (2018) (0)
- Altered immune reconstitution in HIV positive allogeneic stem cell transplant recipients. (2020) (0)
- Virology: Vanquishing HIV (2014) (0)
- Interrupting antiretroviral therapy in HIV cure trials during COVID-19: Adaptation to low transmission settings (2021) (0)
- Reducing time to new HIV diagnosis: time for change in the HIV diagnostic algorithm? (2023) (0)
- 463 CLINICAL OUTCOMES, VIROLOGICAL CHANGES AND FLARES IN WOMEN WITH CHRONIC HEPATITIS B VIRUS INFECTION DURING PREGNANCY AND POST PARTUM (2012) (0)
- Gene therapy as a cure for human immunodeficiency virus (2012) (0)
- Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19 (2020) (0)
- Strategies for an HIV cure: progress and challenges (2018) (0)
- Expanding the toolbox of HIV self‐testing at home: the importance of user choice and feedback (2022) (0)
- Identification of novel hepatitis B virus (HBV) T-cell epitopes and escape mutations in Asian individuals with chronic HBV infection using a population based approach (2009) (0)
- IL7RA single nucleotide polymorphisms are associated with the size and function of the MAIT cell population in treated HIV-1 infection (2022) (0)
- Finding a cure for HIV: The need for science, collaboration and advocacy (2012) (0)
- A common mechanism of clinical HIV-1 resistance to the CCR5 antagonist maraviroc despite divergent resistance levels and lack of common gp120 resistance mutations (2013) (0)
- 4 New HIV specific latency reversing agents with novel targets that synergise with HIV Tat and the bromodomain inhibitor, JQ1 to reactivate HIV from primary cells. (2017) (0)
- The impact of HLA on hepatitis B virus (HBV) sequence polymorphism in Asian individuals with chronic HBV infection (2008) (0)
- Toll-like receptor 7 agonists in people living with HIV: Implications for immunotherapeutic strategies for an HIV cure. (2020) (0)
- 1176 A sensitive, quantitative real-time PCR assay to detect lamivudine resistance-associated mutations in hepatitis B virus (HBV) (2003) (0)
- 564 HIV INFECTION OF CHRONICALLY HEPATITIS B VIRUS (HBV)-INFECTED HUMAN HEPATIC AND STELLATE CELL LINES: IMPLICATIONS FOR PATHOGENESIS OF HIV-HBV CO-INFECTION (2009) (0)
- Ebola and HIV: managing febrile times. (2014) (0)
- Toxicity and in vitro activity of HIV-1 latency-reversing agents in primary CNS cells (2016) (0)
- LPS , immune activation and liver abnormalities in HIV-HBV co-infected individuals on HBV-active combination antiretroviral therapy (2014) (0)
- Research Methods & Reporting: Taking healthcare interventions from trial to practice (2010) (0)
- Functional cure of HIV: the scale of the challenge (2018) (0)
- Persistence of envelopes in different CD4+ T-cell subsets in antiretroviral therapy-suppressed people with HIV (2022) (0)
- Treatment compliance in older patients with melanoma. (2010) (0)
- Chronic HIV Infection Circles Differ After Treatment of Acute and Dynamics of T Cells and TCR Excision (2002) (0)
- Effective Antiretroviral Therapy 1-Infected Individuals on Prolonged Human Immunodeficiency Virus Type Beacons To Detect Virus Replication in Use of Real-Time PCR and Molecular (1999) (0)
- Substantial improvements in performance indicators achieved in a PBMC cryopreservation quality assurance program using single donor samples. (2006) (0)
- Co-culture of T-cells with dendritic cells facilitates HIV latency in proliferating CD4 + T-cells: implications for the establishment and reversal of latency (2015) (0)
- Time-associated changes in cell-associated HIV RNA in HIV-infected subjects on suppressive antiretroviral therapy - implications for clinical trials of cure interventions (2015) (0)
- O17.1 Histone deacetylase inhibitors alter the accumulation of cell-associated spliced hiv mrna – implications for reactivating the reservoir (2015) (0)
- TENOFOVIR-BASED HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART) IS ASSOCIATED WITH HIGH RATES OF HBV DNA SUPPRESSION AND HBEAG SEROCONVERSION IN THAI HIV-HBV COINFECTED PATIENTS (2008) (0)
- Variation in the IL7R gene influences MS risk, response to therapy and immune cell function. (2012) (0)
- Homage to Mark Wainberg (2017) (0)
- INCREASED INNATE AND ADAPTIVE IMMUNE PRESSURE IS RESPONSIBLE FOR THE REDUCED TRANSCRIPTIONAL ACTIVITY OF INTRAHEPATIC COVALENTLY CLOSED CIRCULAR (CCC) DNA THAT OCCURS IN HBEAG-NEGATIVE CHRONIC HEPATITIS B (CHB) (2008) (0)
- Comparison of real-time PCR assays for monitoring serum hepatitis B virus DNA levels during antiretroviral therapy (vol 44, pg 2983, 2006) (2007) (0)
- The Frequency of Cytomegalovirus (CMV)-Specific CD8+ T Cells Distinguishes CMV Clinical Outcomes Following Hematopoietic Allogeneic Stem Cell Transplant: A Prospective Multicentre Cohort Study (2015) (0)
- Corrigendum to: Therapeutics for COVID-19: established and in development (2021) (0)
- Factors associated with weak positive SARS-CoV-2 diagnosis by reverse transcriptase-quantitative polymerase chain reaction (RT-qPCR) (2022) (0)
- The future of genomics in HIV medicine: (628452012-295) (2012) (0)
- CD31(+) naive T-cells are reduced in HIV-infected individuals and are permissive to HIV infection in vitro only following IL-7 stimulation (2005) (0)
- Altered Immune Reconstitution in Allogeneic Stem Cell Transplant Recipients With Human Immunodeficiency Virus (HIV) (2020) (0)
- HBV-related inflammation is linked to the level of genetically intact HIV proviruses (2019) (0)
- 112: The mechanism and application of a superagonistic antibody for human IL-21 (2014) (0)
- NOX2 oxidase expressed in endosomes exacerbates influenza pathogenicity (2016) (0)
- Running title : Aging among treated HIV in Malaysia (2017) (0)
- Novel Markers of Blood and Skin Human Identification of Lineage Relationships and (2012) (0)
- Cured: How the Berlin Patients Defeated HIV and Forever Changed Medical Science (2014) (0)
- Modulation of the CCR 5 receptor / ligand axis by seminal plasma and the utility of in vitro 1 versus in vivo models 2 Running head : Chemokine regulation by semen 3 4 (2019) (0)
- Editorial (2020) (0)
- 42 PREDICTING POST PARTUM HEPATITIS B VIRUS FLARES USING INNATE IMMUNE BIOMARKERS (2013) (0)
- TP023/#1560 A phase 3, randomized, double-blind, placebo/paclitaxel-controlled study of batiraxcept in combination with weekly paclitaxel in patients with platinum-resistant recurrent ovarian cancer (GOG-3059/ENGOT OV-66) (2022) (0)
- Note from the Editors. (2017) (0)
- Reducing the gap between the diagnosis and treatment of HIV infection (2019) (0)
- AIDS A gathering storm: HIV infection and non-alcoholic fatty liver disease (NAFLD) in low and middle-income countries (LMIC) (2018) (0)
- Chidamide reactivates and diminishes latent HIV-1 DNA in patients on suppressive antiretroviral therapy (2018) (0)
- TP019/#1556 PICCOLO: an open-label, single arm, phase 2 study of mirvetuximab soravtansine in recurrent platinum sensitive, high-grade epithelial ovarian cancers with high folate-alpha expression (2022) (0)
- Combination treatment prevents HIV re-emergence in monkeys (2018) (0)
- The role of antigen presenting cells in the induction of HIV-1 latency in resting CD4+ T-cells (2015) (0)
- 31 High prevalence of CXCR4-using virus and low clonal expansion in infected naïve and central memory CD4+ T cells in individuals on ART (2017) (0)
- Statistical analysis of single-copy assays when some observations are zero (2019) (0)
- Editorial: Strategies and barriers for hepatitis B cure: implications for HIV. (2020) (0)
- Killing a Moving Target: ADCC Against HIV-1-infected Cells in the Process of CD4-downregulation (2018) (0)
- Clonal integration site expansion of infected cells is a main contributor of HIV persistence in more differentiated T cell subsets during suppressive ART (2019) (0)
- Pro-fibrogenic role of alarmin HMGB1 in HIV-HBV co-infection. (2022) (0)
- Nanoscale probing and imaging of HIV-1 RNA in cells with a chimeric LNA-DNA sensor. (2022) (0)
- after endotoxin challenge in humans Gene expression profiles of peripheral blood leukocytes (2011) (0)
- 53 TLR2 AND TLR7/8 ACTIVATION PREDICT POST PARTUM HBV FLARES (2012) (0)
- Erratum to: HIV integration sites in latently infected cell lines: evidence of ongoing replication (2017) (0)
- Lessons for the HIV response from structural innovations catalysed by COVID-19 (2022) (0)
- Immune activation markers associated with levels and diversity of intact HIV proviruses during HIV- HBV co-infection (2019) (0)
- Department of Error (2014) (0)
- In memoriam: Professor David Cooper (1949 to 2018) (2018) (0)
- Molecular Evidence of Patient-to-Patient Transmission of Hepatitis E Virus in a Hematology Ward (2009) (0)
- AUTHOR'S CORRECTION Comparison of Real-Time PCR Assays for Monitoring Serum Hepatitis B Virus DNA Levels during Antiretroviral Therapy (2007) (0)
- Unequal distribution of genetically-intact HIV-1 proviruses in cells expressing the immune checkpoint markers PD-1 and/or CTLA-4 (2023) (0)
- Australasian HIV/AIDS Conference 2009 (2010) (0)
- Ablating cellular Inhibitors of Apoptosis (cIAPs) specifically sensitizes HIV-infected CD4 T cells to death, reducing viraemia and immune attrition in humanized mice (2016) (0)
- ExVivo Response to Histone Deacetylase (HDAC) Inhibitors of the HIV Long Terminal Repeat (LTR) Derived from HIV-Infected Patients on Antiretroviral Therapy (2014) (0)
This paper list is powered by the following services:
Other Resources About Sharon Lewin
What Schools Are Affiliated With Sharon Lewin?
Sharon Lewin is affiliated with the following schools:
